SGLT-1 Inhibitors: The Future Class of Diabetes Medication
Eliot Brinton, MD, President of the Utah Lipid Center, explains the potential of liraglutide, semaglutide, and it's related therapies for type 2 diabetes.
Read More
GSK Submits NUCALA for COPD Indications
The biologic agent has shown efficacy in reducing asthma exacerbations and improving patient quality of life.
FDA Roundup of the Week: November 4
Catch up on all the past week's action in US Food and Drug Administration rulings and decisions.
Esbriet for IPF: Reconsidering Its Role
Gordon L. Yung, MD, FCCP, explains the right patient perspective of the antifibrotic therapy.
The Connected Clinician: Top Stories of the Week for November 3
Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of November 3.
Canagliflozin Returns Renal Strengths in CANVAS Trial
Janssen's T2D drug for CV risks is undergoing a kidney disease-based phase 3 trial now.
Excessive Sleep Therapy For OSA Marks Strong Phase 3 Results
Almost 500 patients were split into 4 dosing groups for JZP-110.
Changing Inhalers Does Not Cause Worse Technique
Researchers studied recently-referred COPD patients and what attributes put them at risk for poor inhaler device technique.
Breo Ellipta Proves Non-inferior to Asthma Therapies, Affordable for COPD with CV Risks
Two consecutive CHEST studies showed combination therapy's expanding portfolio.
Dupilumab Adds to Its Uncontrolled Asthma Portfolio
Regeneron and Sanofi released more positive phase 3 trial results, a day following phase 2b results were shared at CHEST.
Do You Know How To Use Your Inhaler?
Less than 40% of patients in a recent study could perform a perfect inhalation with their device. That's a problem for COPD and asthma patients.
Asthma Control Requires a Better Understanding
An expert delves into the machinations of Type 2 asthma inflammation — a common condition in moderate-to-severe asthma patients.
Asthma Death Rates Continue Surprising Drop
The Cleveland Clinic's study of CDC-collected data from 1999 to 2015 showed one age group's resilience to asthma mortality.
Treating the Gray Area of Asthma/COPD Overlap
While advanced therapies approved for either should be considered for ACO patients, there hasn't be sole investigations.
The Sleep Apnea Problem for Truck Drivers
A recent survey found that 85% of commercial drivers tested for the sleeping condition tested positive for it.
Patient Family Members Report Anxiety, Limited Knowledge of Acute Care
A Florida questionnaire showed that only one-third of patients’ family members were satisfied with their level of knowledge.
Researchers Draw Association Between Asthma Rates, Urgent Care, and NYC Pollutants
Nitrogen dioxide, particulate matter, elemental carbon, and winter average sulfur dioxide were more prevalent in high asthma prevalence neighborhoods.
Physician Residents Report Confusion Over Marijuana Pharmacology
Despite medical cannabis being legalized in 28 states, a majority of future internists expressed concern for their limited knowledge.
MD Magazine's Top 10 Stories for October
Catch up on our biggest headlines you missed before the end of the month!
FDA Roundup of the Week: October 28
The Connected Clinician: Top Stories of the Week for October 27
Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of October 27.
Alkermes Announces Schizophrenia Therapy Studies
ARISTADA is being investigated as a possible extended-release injectable suspension, as well as INVEGA SUSTENNA in patients with acute exacerbation of schizophrenia.
How Specialists Are Addressing Heart Failure
Mark E. Dunlap, MD, tells MD Magazine about team-based approach and advancing technology's role in cardiovascular care.
Risankizumab Scores Well Versus Psoriasis Competitors
The AbbVie investigational drug hit endpoints in 3 pivotal phase 3 trials.
FDA Generic Approvals Are Rising Without Plans to Stop
The most recent fiscal year reached a new peak in total approvals — for the 3rd year in a row.
FDA Requests More Trial Data for Translarna for DMD
A Complete Response Letter from the FDA indicated a need for more evidenced trial data.
GOCOVRI for Dyskinesia Gets Orphan Drug Designation
The FDA approved oral amantadine capsules for a 7-year orphan drug exclusivity.
How Rising Heart Failure Rates Can Be a Good Thing
Mark Dunlap, MD, explained to MD Magazine the future of cardiovascular disease response and rates.
FDA Fast-Tracks Possible Alzheimer's Modifier
ALZ-801 from Alzheon Inc. has the potential to combat an underlying pathology of AD.
FDA Approves Soliris for Generalized Myasthenia Gravis
Eculizumab showed efficacy for the neuromuscular disease in a randomized phase 3 study.